Physician profile
Thomas Wenker
NPI 1194926014
$3,228.80
in general payments reported to CMS, 2019-2025
12 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.43 · 2021: $11.19 · 2022: $602 · 2023: $640 · 2024: $789 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.41 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,050.29 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $426.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $318.31 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $90.57 | 2022-2025 | Nemluvio |
| Lilly USA, LLC | $79.38 | 2023-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $60.30 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $47.12 | 2023-2025 | Zoryve |
| Amgen INC. | $44.67 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $40.57 | 2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $36.54 | 2019-2022 | |
| Janssen Biotech, INC. | $21.00 | 2024 | Tremfya |
| Biofrontera INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wenker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.